Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC
Status:
Terminated
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
In this study, the investigators will investigate toxicity in patients treated with a
Programmed cell death protein 1 (PD-1) inhibitor and radiotherapy. Patients with advanced
Non-Small Cell Lung Cancer (NSCLC) can be included when treatment with a PD-1 inhibitor is
indicated according to national guidelines. Included patients will receive stereotactic
radiotherapy to one or two tumour lesion(s) in addition to the PD-1 inhibitor, and toxicity
is the primary endpoint.